Management of Moderate to Severe COPD
Rationale for Triple Therapy
- The European Respiratory Society recommends adding a LABA/ICS combination to tiotropium for patients with moderate to severe COPD who remain symptomatic on LAMA monotherapy, as it reduces severe exacerbations and improves symptoms 1, 2
- The American Thoracic Society suggests that the LABA/ICS combination improves health-related quality of life and reduces the risk of moderate or severe COPD exacerbations when added to existing therapy 1, 2, 3
- The stepwise approach of adding LABA/ICS to tiotropium maintains the proven benefits of tiotropium while addressing residual symptoms and exacerbation risk 1, 2
Evidence Supporting This Approach
- The European Respiratory Society guideline evidence strongly supports adding rather than switching, as LAMAs have demonstrated superiority over LABAs alone in reducing COPD exacerbations, exacerbation-related hospitalizations, and adverse effects 1, 2, 3
- The American College of Chest Physicians states that when LABA/ICS was directly compared to LAMA alone, they were equivalent for exacerbation prevention, with some outcomes favoring the LABA/ICS combination 1, 2
- The combination of all three medication classes provides additive benefits that exceed what can be achieved with dual therapy, according to the Global Initiative for Chronic Obstructive Lung Disease 1, 2, 3
Alternative Dual Bronchodilator Option
- The European Respiratory Society recommends that LABA/LAMA combinations increase lung function to a greater degree than LAMA alone 1
- Adding a LABA alone to create LAMA/LABA dual bronchodilation avoids the increased pneumonia risk associated with inhaled corticosteroids, as suggested by the American Thoracic Society 1, 2, 3
Important Caveats
- The European Respiratory Society warns that the LABA/ICS combination carries an increased risk of pneumonia, though this effect may vary among different formulations 1, 2, 3
- The American College of Chest Physicians states that patient phenotype matters, as patients with a history of chronic bronchitis and frequent exacerbations respond better to preventative therapy 2, 3